By acting as an immune modulator, an adjuvant, or an immune stimulator to activate both adaptive and innate immune cells, HP-NAP is a potential immunotherapeutic agent to improve the clinical outcome of cancer treatment. The gene discussed is CTNNBL1; the disease is cancer.